{"id":1683,"date":"2025-06-13T11:55:38","date_gmt":"2025-06-13T09:55:38","guid":{"rendered":"https:\/\/alcove.crosss3.eu\/alcove-research-project\/"},"modified":"2026-03-04T10:50:18","modified_gmt":"2026-03-04T09:50:18","slug":"alcove-research-project","status":"publish","type":"page","link":"https:\/\/alcove.crosss3.eu\/en\/alcove-research-project\/","title":{"rendered":"Alcove research project"},"content":{"rendered":"\n
\n
\n
\n
\n
\"\"<\/figure>\n<\/div>\n<\/div>\n\n\n\n
\n
\n

The ALCOVE research project<\/strong>, coordinated by Lille University Hospital,<\/strong> focuses on the early detection of lung cancer, one of the leading causes of cancer\u2011related deaths in Europe.
The burden is particularly significant in the Hauts\u2011de\u2011France, Grand Est, and Belgium, where historical industrial exposure and high smoking rates have contributed to an increased incidence of the disease. <\/p>\n<\/div>\n\n\n\n

\n
\n

The ALCOVE consortium is working to develop an electronic\u2011nose device capable of detecting volatile organic compounds (VOCs) associated with lung cancer in exhaled breath.
This non\u2011invasive technology relies on advanced sensors and analytical algorithms to help identify individuals who may be at higher risk and guide them toward appropriate medical imaging\u2013based screening. <\/p>\n\n\n\n

ALCOVE brings together cross\u2011border scientific and clinical experts to validate the effectiveness of an electronic\u2011nose device\u2014currently a laboratory\u2011tested prototype\u2014in a real\u2011world hospital environment.
The goal is to eventually deploy this technology in large\u2011scale lung cancer screening programs.
This initiative represents a significant advance in lung cancer care, offering an innovative solution to a major public health challenge. <\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n

\n
<\/div>\n\n\n\n
\n

Objectives<\/mark><\/h2><\/div>\n<\/div>\n\n\n\n
\n
<\/div><\/div>
\n

2024-2026<\/mark><\/strong><\/p><\/div>\n

01<\/strong><\/p>\n\n\n\n

Develop a series of miniaturized electronic\u2011nose prototypes<\/strong> that meet hospital\u2011environment requirements in accordance with European medical device regulations.<\/p>\n<\/div><\/div><\/div>

<\/div><\/div>

2024-2026<\/mark><\/strong><\/p><\/div><\/div><\/div>\n\n\n\n

2026-2028<\/mark><\/strong><\/p><\/div>\n

02<\/strong><\/p>\n\n\n\n

Evaluate the device\u2019s performance in clinical settings <\/strong>that closely reflect real\u2011world conditions expected in future screening programs.<\/mark><\/p>\n<\/div><\/div><\/div>

<\/div><\/div>

2026-2028<\/mark><\/strong><\/p><\/div><\/div><\/div>\n\n\n\n

2028 et au-del\u00e0<\/mark><\/strong><\/p><\/div>\n

03<\/strong><\/p>\n\n\n\n

Prepare the integration of the device into upcoming regional lung cancer screening <\/strong>initiatives and support its adoption by health care professionals<\/strong>.<\/mark><\/p>\n<\/div><\/div><\/div>

<\/div><\/div>

2028 et au-del\u00e0<\/mark><\/strong><\/p><\/div><\/div><\/div>\n\n\n\n

2028 et au-del\u00e0<\/mark><\/strong><\/p><\/div>\n

04<\/strong><\/p>\n\n\n\n

Transfer the electronic\u2011nose technology to an industrial partner<\/mark><\/strong> for market deployment.<\/p>\n<\/div><\/div><\/div>

<\/div><\/div>

2028 et au-del\u00e0<\/mark><\/strong><\/p><\/div><\/div><\/div>\n<\/div><\/div>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
<\/div>\n\n\n\n
\n
\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n
\n
\n
\"\"<\/figure>\n\n\n\n
\n
\"\"<\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n

2018 – 2022<\/p>\n\n\n

PATHACOV<\/strong>: the starting point for ALCOVE<\/strong><\/mark><\/h2>\n\n\n

We aim to build on the momentum created by the PATHACOV project through ALCOVE, continuing to advance innovation and improve lung cancer screening.<\/p>\n\n\n\n

\n
Discover the project<\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
<\/div>\n\n\n\n
\n
<\/div>\n\n\n\n
\n

Project leader<\/h2><\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n